FR2224133A1 - Modified interferons with anti-viral activity - having prolonged half-lives in vivo - Google Patents

Modified interferons with anti-viral activity - having prolonged half-lives in vivo

Info

Publication number
FR2224133A1
FR2224133A1 FR7411747A FR7411747A FR2224133A1 FR 2224133 A1 FR2224133 A1 FR 2224133A1 FR 7411747 A FR7411747 A FR 7411747A FR 7411747 A FR7411747 A FR 7411747A FR 2224133 A1 FR2224133 A1 FR 2224133A1
Authority
FR
France
Prior art keywords
modified
lives
vivo
viral activity
asialo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7411747A
Other languages
French (fr)
Other versions
FR2224133B1 (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandoz AG
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CH480273A external-priority patent/CH601336A5/xx
Application filed by Sandoz AG filed Critical Sandoz AG
Publication of FR2224133A1 publication Critical patent/FR2224133A1/en
Application granted granted Critical
Publication of FR2224133B1 publication Critical patent/FR2224133B1/fr
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Interferons can be modified by (a) enzymic introduction of a terminal sialic acid residue, using a sialic acid donor, e.g. CMP-N-acetyl nemaminic acid and a silyl transfer ase, at pH 5.5-8.0, (b) oxdn. of the terminal galactose residue of an asialo-interferon with galactose at pH 7.0-8.0, (c) removal of the terminal galactose residue of an asialo-interferon with a beta-galactosidase at pH 3.5-6.5, (d) biosynthesis under modifying conditions, i.e. in the presence of a glycosyl transferase inhibitor, e.g. 2-deoxyglucose. (Modified) interferous can be purified by affinity chromatography using an agglutin immobilised or activated agarose.
FR7411747A 1973-04-04 1974-04-03 Modified interferons with anti-viral activity - having prolonged half-lives in vivo Granted FR2224133A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH480273A CH601336A5 (en) 1973-04-04 1973-04-04
CH480173 1973-04-04

Publications (2)

Publication Number Publication Date
FR2224133A1 true FR2224133A1 (en) 1974-10-31
FR2224133B1 FR2224133B1 (en) 1977-11-10

Family

ID=25696314

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7411747A Granted FR2224133A1 (en) 1973-04-04 1974-04-03 Modified interferons with anti-viral activity - having prolonged half-lives in vivo

Country Status (10)

Country Link
JP (1) JPS5728557B2 (en)
AU (1) AU6757374A (en)
DD (3) DD116621A5 (en)
DE (1) DE2416019A1 (en)
DK (1) DK138381B (en)
ES (3) ES424857A1 (en)
FR (1) FR2224133A1 (en)
NL (1) NL7404424A (en)
PL (1) PL88697B1 (en)
SE (2) SE7714085L (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0080032A3 (en) * 1981-11-20 1985-11-13 Enzo Biochem, Inc. Pharmaceutical preparation for treating herpetic lesions

Also Published As

Publication number Publication date
ES446529A1 (en) 1977-10-16
ES446530A1 (en) 1977-11-01
ES424857A1 (en) 1976-12-16
SE7714085L (en) 1977-12-12
NL7404424A (en) 1974-10-08
SE7714086L (en) 1977-12-12
DD116058A5 (en) 1975-11-05
PL88697B1 (en) 1976-09-30
DD116621A5 (en) 1975-12-05
DD118436A5 (en) 1976-03-05
DK138381B (en) 1978-08-28
JPS5728557B2 (en) 1982-06-17
DE2416019A1 (en) 1974-10-24
JPS49134826A (en) 1974-12-25
DK138381C (en) 1979-04-09
FR2224133B1 (en) 1977-11-10
AU6757374A (en) 1975-10-09

Similar Documents

Publication Publication Date Title
Wilcox et al. Transfer RNA as a cofactor coupling amino acid synthesis with that of protein.
AU500397B2 (en) Stabilizer assembly
ES8701717A1 (en) Amino-salicylic acid derivatives and pharmaceutical compositions.
EP0175699A4 (en) Bacterial strains.
Lee et al. Galactosidases from Aspergillus niger
FR2224133A1 (en) Modified interferons with anti-viral activity - having prolonged half-lives in vivo
BE813308A (en) Modified interferons with anti-viral activity - having prolonged half-lives in vivo
DE3569112D1 (en) 4,5-dihydro-4-oxo-2- û(2-trans-phenylcyclopropyl)amino¨-3-furancarboxylic acids and derivatives thereof
DE3280127D1 (en) GENETICALLY MODIFIED MICROORGANISMS.
GB2213010B (en) High speed disconnectable d.c. amplifier with bias-current compensation in disconnected state.
GB2136652B (en) Differential amplifier with bipolar transistors
DK277985D0 (en) GLYCOPROTEIN WITH ANTITUMORAL EFFECT AND PROCEDURE FOR PREPARING THEREOF
EP0294309A3 (en) Stabilizers for improving the fastness of dyes
EP0218416A3 (en) Kibdelosporangium aridum sk&f-aad-609
JPS578783A (en) Production of fructosyl transferase enzyme
AU555272B2 (en) Enzyme and production of isomaltulose
ES446895A1 (en) Amino acid parenteral solution containing reducing sugar
CA940576A (en) Self aligning and self adjusting thrust bushing assembly
DE3663764D1 (en) Differential amplifier with nmos transistors
Zelinsky The enzymatic incorporation of paratose residues into O-specific polysaccharides of Salmonella.
FR2216992A1 (en) Low MW, purified collagenase prepn - by ion-exchange chromatography of enzyme from first-stage larvae of hypoderma spp.
FR2034572A1 (en) Ellaginic acid salts
ZA846388B (en) Alpha-allenic-alpha-amino acids
ATE68649T1 (en) LINE DEFLECTION CIRCUIT WITH RASING DISTORTION CORRECTION.
FR2146943A1 (en) Thrombolytic enzyme - from streptomyces venetus

Legal Events

Date Code Title Description
ST Notification of lapse